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pelvis and head and neck, in lung instead, gamma pass rates 
were lower in 4/5 cases.  
 
Conclusion: DC is a suitable tool for VMAT in vivo dosimetry. 
The pencil beam algorithm can be inaccurate in the presence 
of low-density inhomogeneities. 
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Purpose or Objective: Accurate beam modelling is an 
essential function of a treatment planning system (TPS) to 
ensure that plans can be calculated that are deliverable 
within clinically acceptable tolerances. The purpose of this 
work is to evaluate the computed integral depth dose (IDD) 
curves of four commercially available proton TPSs, 
benchmarked against measured data. The four TPSs 
(EclipseTM, XiO®, Pinnacle3, RayStation®) were 
commissioned using pencil beam scanning data from the 
University of Pennsylvania (UPenn) facility. 
 
Material and Methods: A water cube phantom (40cm3) was 
created in each TPS for calculation of IDD curves. Calculation 
grid size set to 1mm in all TPSs. Individual IDDs for 27 
nominal energies, ranging from 100 to 226.7MeV, were 
calculated by integrating the calculated depth dose 
distributions. These were all benchmarked against measured 
data from UPenn, comparing the clinical range at 80% distal 
dose (D80), Bragg peak width between distal and proximal 
80% (D80-P80), range at 0.5% (R0.5), and distal penumbra 
between D80 and R0.5. Gamma-index analysis with pass 
criteria of 1mm/1% was also used to compare computed and 
measured IDDs. 
 
Results: Mean percentage of IDDs with >95% pass rate for 
1mm/1% criteria were 96.7% (SD 4.9) for XiO®, 94.1% (SD 8.9) 
for EclipseTM, 95.4% (SD 8.6) for RayStation®, and 49.2 (SD 
26.0) for Pinnacle3. Maximum differences between computed 
and measured IDD data are shown below. No correlation with 
nominal energy was observed. 
 
 
Conclusion: Characteristics of computed IDDs were compared 
to measured data for four commercially available TPSs. All 
were within clinically acceptable tolerances, with XiO 
showing the closest agreement. Differences observed were 
attributed to TPS specific beam modelling. Further 
investigation will assess the cumulative impact of these 
discrepancies on verified clinical treatment plans. 
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Purpose or Objective: One of the clinical issues our institute 
faces regarding in vivo EPID dosimetry is the number of raised 
alerts. For example, alerts are raised for 49% of the 
treatments in case of head-and-neck (H&N) VMAT 
treatments; an alert is raised when dosimetry results are 
found deviating according to statistics derived from the 
histogram of 3D γ-analysis results. These alerts are mostly 
found to be patient-related or attributable to limitations of 
our back-projection and dose calculation algorithm. After 
inspection, an intervention is considered for only 0.3% of the 
treatments. The purpose of this study is to develop a 
principal component analysis (PCA) based classification 
method to improve the specificity of our EPID dosimetry 
system. In particular, in contrast to our current classification 
method, PCA allows for the spatial distribution of γ-values to 
be taken into account for deviation detection. 
 
Material and Methods: The input for PCA consisted of 3D γ-
distributions (3%/3mm), one per treatment arc per fraction. 
In total, 2024 3D γ-distributions from 499 H&N VMAT 
treatment-plans were included. As an initial choice, 
components describing at least 1% of the variance were 
selected. The distribution of variances over the components 
was inspected to validate this choice. Using these 
components, new 3D γ-distributions were created by 
projecting each input 3D γ-distribution on only these 
components and then projecting the result to the original 
coordinate system of the 3D γ-distributions. If the selected 
components describe the original γ-distribution well, the new 
and original γ-distributions will be similar. This similarity was 
quantified by the root mean square (RMS) d of the difference 
between the two γ-distributions; a γ-distribution was marked 
as deviating when d exceeded a threshold. All true positive γ-
distributions (n = 2) in the dataset, as identified by 
experienced medical physicists, were used to determine this 
threshold for identification of alerts. 
 
Results: The first 16 components were each found to 
describe at least 1% of the variance; cumulatively, they 
account for 83% of the variance in the dataset. Figure 1 
shows the cumulative variance accounted for as a function of 
selected components and indicates that the choice for 
selecting components is reasonable. After finding and 
applying the appropriate threshold for detecting the 
identified true positives, a drop in alert rate from 49% to of 
11% was observed, corresponding to an increase in specificity 
from 0.51 to 0.89. 
 
 
 
Conclusion: The PCA-based classification method presented 
in this study enhances the specificity of deviation detection 
in 3D in vivo EPID dosimetry of H&N VMAT from 0.51 to 0.89, 
compared to our current clinical γ-histogram based method. 
Before clinical implemention, a rigorous validation is 
required. 
 
PO-0828  
Dosimetric assessment of a second generation Multi-Leaf 
Collimator for robotic radiotherapy 
P.H. Mackeprang
1Division of Medical Radiation Physics and Department of 
Radiation Oncology Inselspital, Bern University Hospital, and 
University of Bern, Switzerland 
1, D. Schmidhalter1, D. Henzen1, M. 
Malthaner1, D.M. Aebersold1, P. Manser1, M.K. Fix1 
 
